Fox19: 'Chemobrain' and music

UC DAAP expert discusses collaborative project using a music app to address chemobrain in patients

portrait of Claudia Rebola

Claudia Rebola, PhD, associate dean for research and associate professor in industrial design for DAAP. “I am always fascinated by ways to embrace the creative disciplines to help people and improve their well-being and quality of life through the use of design," she says. Photo/UC Creative + Brand

Music as medicine has become a more widely adopted concept. Now, UC experts at the College of Design, Architecture, Art and Planning are working with colleagues at the UC Gardner Neuroscience Institute and the UC Cancer Center to blend music with recovery for patients who have undergone chemotherapy as part of treatment.  

This collaborative project — a music app — evolved from the ideas of experts at the UC College of Medicine who wanted to help patients and survivors experiencing "chemobrain".

Claudia Rebola, PhD, associate dean for research and associate professor in industrial design for DAAP, spoke to Fox19 about the creation of the app.

Watch the Fox19 segment.

Read the full UC News story.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

1

UC biologist talks about 'pearmageddon'

March 16, 2026

WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.